Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ultragenyx proposes to acquire Dimension Therapeutics
The Ultragenyx offer represents a premium of over 358% to Dimension's unaffected share price as of August 24, 2017 and premiums of 24% and 48% over the implied
The Ultragenyx offer represents a premium of over 358% to Dimension's unaffected share price as of August 24, 2017 and premiums of 24% and 48% over the implied
The cancer drug was evaluated in the late-stage study dubbed MURANO in combination with MabThera/Rituxan (rituximab) in CLL patients whose disease had relapsed or is in the refractory
The company signed two sale agreements to generate total proceeds of $2.48bn. Under the first deal, CVC Capital Partners Fund VI will acquire Teva’s women’s health product portfolio across contraception, fertility,
Proposed to have a brand name of Trelegy Ellipta, FF/UMEC/VI has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP) in
Under the deal, BMS will use Halozyme’s Enhanze drug-delivery technology to develop subcutaneously administered immuno-oncology medicines. Enhanze technology is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20),
It is the first biosimilar approved in the US to treat cancer. Mvasi has been approved to treat certain colorectal, brain, lung, kidney and cervical cancers in adult patients. The drug also
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) had unanimously voted that the data tabled by GSK supported the efficacy and safety of its shingles candidate
The top-line data from the trial has demonstrated that the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in patient with epidermolysis
Livatag could not improve survival of the HCC patients when compared to best standard of care according to the findings of the phase 3 trial dubbed as ReLive.
The Johnson & Johnson company said that by stopping development of JNJ-4178, its investigational hepatitis C treatment regimen, it would focus on addressing significant unmet needs in chronic